What's Going On With Palisade Bio Stock On Thursday?
What's Going On With Palisade Bio Stock On Thursday?
The Common Warrants will have an exercise price of $1.40 per share, will be exercisable at issuance, and will have a term expiring five years from issuance.On Thursday, Palisade Bio Inc (NASDAQ:PALI) stock is trading higher with a strong session volume of 26.97 million, compared to an average volume of 107.68k as per data from Benzinga Pro.
在星期四，Palisade Bio Inc (納斯達克:PALI) 的股票交易價格上漲，成交量達到2697萬，而根據Benzinga Pro的數據，平均成交量爲10.768萬。
Palisade Bio priced an underwritten public offering for gross proceeds of approximately $5 million.
Palisade Bio定價了一項承銷的公開發行，預計總收益約爲500萬美元。
The offering comprises 158,000 Class A Units and 3.12 million Class B Units. The price per Class A Unit is $1.525, and the price per Class B Unit is $1.5249.
此次發行包括158,000個A類單位和312萬個B類單位。每個A類單位的價格爲1.525美元，每個B類單位的價格爲1.5249美元。
The Common Warrants will have an exercise price of $1.40 per share, will be exercisable at issuance, and will have a term expiring five years from issuance.
普通Warrants的行使價格爲每股1.40美元，發行時即可行使，行使期限在發行後五年到期。
The company will use the net proceeds primarily to fund the Phase 1 trial of PALI-2108, pre-clinical studies, research and development, and working capital.
公司將主要使用淨收益資助PALI-2108的第一階段試驗、臨床前研究、研發及營運資金。
Last week, Palisade Bio revealed preliminary results from its first three single ascending dose (SAD) cohorts in its ongoing Phase 1 human study for PALI-2108 for Ulcerative Colitis.
上週，Palisade Bio公佈了其正在進行的針對PALI-2108用於潰瘍性結腸炎的第一階段人體研究的前三個單次遞增劑量（SAD）組的初步結果。
Preliminary results appear to indicate that PALI-2108 was safe and well tolerated in the first three cohorts (n=24; 6:2 active to placebo) at 15mg, 50mg, and 150mg, with no treatment-related dose reductions, no Treatment-Related Adverse Events (TRAEs), no Serious Adverse Events (SAEs), and no treatment-related lab abnormalities in any subject.
初步結果似乎表明，PALI-2108在前三個組別（n=24；6:2有效對照）中安全且耐受良好，劑量分別爲15mg、50mg和150mg，沒有治療相關的劑量減少，沒有治療相關的不良事件（TRAEs），沒有嚴重不良事件（SAEs），也沒有任何受試者出現治療相關的實驗室異常。
Preliminary pharmacokinetics data from the first cohorts demonstrated delayed release of the PDE4 inhibitor active suggesting PALI-2108 is performing as designed with colonic bioactivation.
來自首個組別的初步藥代動力學數據表明PDE4抑制劑活性延遲釋放，表明PALI-2108在結腸生物活化方面表現符合預期。
Based on the findings with this preliminary safety data, the company is advancing toward its planned crossover study to evaluate the effects of food on pharmacokinetics, followed by multiple ascending dose (MAD) cohorts and, finally, a multiple-dose cohort of patients with Ulcerative Colitis.
根據這些初步安全數據的發現，該公司正在推進其計劃中的交叉研究，以評估食物對藥物代謝動力學的影響，隨後是多次遞增劑量（MAD）隊列，最後是潰瘍性結腸炎患者的多次給藥隊列。
The company is on track to report topline data from this study in the first half of 2025.
該公司計劃在2025年上半年報告本研究的初步數據。
As of September 30, the company had cash and cash equivalents of $8.0 million. The company believes it has sufficient cash to fund its planned operations through the first quarter of 2025.
截至9月30日，該公司持有現金及現金等價物800萬美元。公司認爲其有足夠的現金來資助其計劃的運營，直到2025年第一季度。
Price Action: PALI stock is trading 51.5% higher at $2.12 at last check Thursday.
價格動態：PALI股票在上週四的最後檢查時交易上漲51.5%，至2.12美元。
- 3D Systems Agrees To Sell Geomagic Portfolio For $123 Million, AI And 3D Printing Take Center Stage
- 3D系統同意以12300萬美元的價格出售Geomagic產品組合，人工智能和3D打印成爲焦點。
